Autologous Anti-H3.3K27M TCR-expressing T-cells Therapy(University of California, San Francisco)

N/A

Report date: 2022/08/01 13:16:27

Base Information

Drug NameAutologous Anti-H3.3K27M TCR-expressing T-cells Therapy(University of California, San Francisco)
Drug Alias NameAutologous Anti-H3.3K27M TCR-expressing T-cellsKIND T cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacementsHistone H3.3 K27M antagonists
TargetsHistone H3.3 K27M
Therapy Area/IndicationsDiffuse midline gliomaGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California, San Francisco Fresno
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California, San Francisco FresnoUniversity Of California San Francisco
Inactive CompaniesN/A
Active IndicationsDiffuse midline gliomaGlioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A